Core Insights - DaVita is presenting six new studies at the ASN Kidney Week 2025, focusing on advancements in kidney care, including GLP-1 receptor agonists, middle molecule clearance, and improved access to transplantation and end-of-life care [1][2][3] Research Highlights - The study titled "GLP-1 Receptor Agonist Use Associated with Improvement in Hospitalization Rates in Patients with ESKD" suggests that GLP-1 receptor agonists may reduce hospitalizations for patients with end-stage kidney disease [2] - DaVita's research emphasizes the importance of middle-molecule clearance in dialysis, addressing the removal of larger molecules linked to chronic inflammation and cardiovascular issues [3] Company Commitment - DaVita celebrates 25 years of clinical innovation, focusing on enhancing the quality of life for kidney disease patients rather than just extending life [4] - The company serves approximately 293,200 patients across 3,247 outpatient dialysis centers globally, with a significant presence in the United States [7]